Revidia Therapeutics Inc., a cardiac regenerative medicine company developing first-in-class small molecule drug therapies for heart injury, has announced that it has expanded its leadership team in ...

A new study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and ...

"By understanding how these proteins function differently in various tissues, we're one step closer to designing treatments that target the root causes of DMD." The study reveals that dystrophin's ...

At the moment the only approved therapies are exon-skipping or stop codon read-through drugs, designed to restore dystrophin function in DMD patients with specific mutations in the dystrophin gene.

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

New study reveals crucial protein interactions in Duchenne Muscular Dystrophy, opening doors to more precise and effective ...

Newer therapies like PGN-EDO51 that target exon skipping are considered promising pathways to slow disease progression by restoring partial dystrophin function.

The results suggest that prolonging ambulation may not adversely impact cardiac function in adulthood for patients with ...

Capricor's biologics license application for deramiocel (CAP-1002) is draws largely on the Phase 2 HOPE-2 trial and its ...